What was the overall market valuation of the US migraine drugs market in 2024?

The overall market valuation was $1149.29 Million in 2024. Read More

What is the projected market valuation for the US migraine drugs market by 2035?

The projected valuation for 2035 is $1705.24 Million. Read More

What is the expected CAGR for the US migraine drugs market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 3.65%. Read More

Which companies are considered key players in the US migraine drugs market?

Key players include AbbVie Inc, Amgen Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, and Pfizer Inc. Read More

What were the valuations for abortive and preventive drugs in the US migraine drugs market?

Abortive drugs were valued between $300.0 Million and $450.0 Million, while preventive drugs ranged from $400.0 Million to $600.0 Million. Read More

How do the valuations of CGRP inhibitors and triptans compare in the US migraine drugs market?

CGRP inhibitors were valued between $200.0 Million and $400.0 Million, whereas triptans had a valuation range of $249.29 Million to $305.24 Million. Read More

What are the different routes of administration for migraine drugs and their respective valuations?

Oral administration was valued between $500.0 Million and $750.0 Million, injectable between $400.0 Million and $600.0 Million, and nasal between $249.29 Million and $355.24 Million. Read More

What therapeutic classes are included in the US migraine drugs market and their valuations?

Therapeutic classes include NSAIDs valued between $300.0 Million and $450.0 Million, ergots from $150.0 Million to $200.0 Million, and beta blockers from $400.0 Million to $600.0 Million. Read More

What is the market segmentation based on patient demographics in the US migraine drugs market?

The market segmentation indicates adults valued between $800.0 Million and $1150.0 Million, children from $200.0 Million to $300.0 Million, and geriatrics between $149.29 Million and $255.24 Million. Read More

How does the US migraine drugs market's growth potential appear for the future?

The market's growth potential appears promising, with a projected increase to $1705.24 Million by 2035, reflecting a robust demand for migraine treatments. Read More

US Migraine Drugs Market

US Migraine Drugs Market Research Report: Size, Share, Trend Analysis By End-User (Hospitals And Clinics, Retail Pharmacy, Online Pharmacy, Others), By Types (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices) and By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.65%

2024 Market Size

$ 1,149.29 Million

2035 Market Size

$ 1,705.24 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/17894-HCR | Pages: 100 | Author: Rahul Gotadki, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Abortive Drugs
  2. 4.1.2 Preventive Drugs
  3. 4.1.3 CGRP Inhibitors
  4. 4.1.4 Triptans
2. 4.2 Construction, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Injectable
  3. 4.2.3 Nasal
3. 4.3 Construction, BY Therapeutic Class (USD Million)
  1. 4.3.1 NSAIDs
  2. 4.3.2 Ergots
  3. 4.3.3 Beta Blockers
  4. 4.3.4 Antidepressants
4. 4.4 Construction, BY Patient Demographics (USD Million)
  1. 4.4.1 Adults
  2. 4.4.2 Children
  3. 4.4.3 Geriatrics
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Amgen Inc (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Boehringer Ingelheim GmbH (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca PLC (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis AG (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GlaxoSmithKline PLC (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY THERAPEUTIC CLASS
5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY THERAPEUTIC CLASS, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Migraine Drugs Market Segmentation

US Migraine Drugs Market By Type (USD Million, 2025-2035)

Abortive Drugs
Preventive Drugs
CGRP Inhibitors
Triptans

US Migraine Drugs Market By Route of Administration (USD Million, 2025-2035)

Oral
Injectable
Nasal

US Migraine Drugs Market By Therapeutic Class (USD Million, 2025-2035)

NSAIDs
Ergots
Beta Blockers
Antidepressants

US Migraine Drugs Market By Patient Demographics (USD Million, 2025-2035)

Adults
Children
Geriatrics

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”